HomeFundingMedtech startup 52 North Health scales up its mission to improve chemotherapy...

Medtech startup 52 North Health scales up its mission to improve chemotherapy treatments

UK-based startup 52 North Health has just been awarded a €1.38 million (£1.2 million) grant from Innovate UK’s Smart Grant programme to bring safer and more effective care to patients undergoing chemotherapy. The medtech startup now plans to scale up its solution. 

Chemotherapy is a predominant form of cancer treatment that uses powerful chemicals to kill fast-growing cells in your body. It’s a treatment that aims to stop cancer cells from reproducing, which prevents them from growing and spreading in the body. For patients, chemotherapy can be a lifeline, but it is incredibly intense on the body, and for some, can even have fatal side-effects, namely, neutropenic sepsis (NS).

Medtech company 52 North Health has developed a solution that aims to provide safer and more effective care to patients undergoing chemotherapy – NeutroCheck. Now, the startup has received a grant of €1.38 million (£1.2 million) to scale up development and hit key clinical milestones in order to bring the solution to patients. 

The details: 

  •  €1.38 million (£1.2 million) from Innovate UK’s Smart Grant programme
  • Follows a smaller award made to 52 North Health in January 2020
  • Composes of a 21-month collaboration between 52 North Health, Macmillan Cancer Support, UK Sepsis Trust, UnifAI Technology and Cambridge University Hospitals

Umaima Ahmad, CEO of 52 North Health: “We are delighted to be collaborating with a brilliant and diverse set of partners on this important project which will further propel the value of the NeutroCheck solution and take it through its first clinical trial. This endorsement, our second Smart Grant from Innovate UK, is so important and allows our brilliant teams to focus on getting the NeutroCheck innovation to as many patients as possible throughout the country, so that we can make care for cancer patients across the NHS safer and more effective.” 

It’s reported that every day, 3 people across England and Wales lose their lvies as a result of neutropenic sepsis (NS). Due to the fatality risk associated with NS, all patients undergoing chemotherapy who feel unwell are currently required to go directly to A&E, where they receive strong precautionary antibiotics and undergo a full blood test. Half of the patients are subsequently found not to be at risk, and many patients are not receiving their antibiotics quickly enough, endangering their chances of survival. 

Founded in 2018, 52 North Health want to change this outlook. The UK-based team has decoped NeutroCheck – a solution that composes a small, portable device and a digital platform, which assesses a patient’s risk at home through a blood finger-prick, helping doctors to accurately triage patients, with those at-risk prioritised, and allowing those not at-risk to stay home or instead be seen in the community. 

Tanya Humphreys, Head of Innovation Partnerships at Macmillan explained: “Neutropenic sepsis is a life-threatening condition and its monitoring can be very stressful for people with cancer undergoing chemotherapy. The NeutroCheck device has the potential to empower patients to take more control of their care and could have a significant positive impact on their quality of life. We are delighted to be supporting 52 North Health through this grant to ensure that people with cancer and their carers are meaningfully involved in the development of the Neutrocheck device. This is also a fantastic opportunity for us to collaborate with all the partners to make a big difference for people with cancer.”

With this funding, the startup will be able to accelerate the process of bringing NeutroCheck to the patients who need it most. It’ll do so by collaborating with UnifAI Technology, whose AI-powered digital reader will be incorporated in the solution; Cambridge University Hospitals NHS Foundation Trust, where the trials will be held; and key charity partners in Macmillan Cancer Support and the UK Sepsis Trust, with the shared goal to provide safe and more effective care to patients undergoing chemotherapy. 

Dr Ron Daniels, Intensive Care Doctor and Founder and Chief Executive of the UK Sepsis Trust: “Although sepsis can affect people of any age, certain groups of people are at higher risk, and none more so than those undergoing chemotherapy. These patients are already going through enough trauma, so any device designed to guide as to whether or not they need to seek urgent hospital assessment is invaluable – not to mention the positive impact on a stressed NHS. We have partnered with 52 North Health because they have a true understanding of the need: the development of a device for use in the patient’s own home, which uses existing and highly relevant markers of risk is absolutely the right approach.” 

Now, the startup plans to get ready for clinical validation.

Dr Hugo Ford, lead cancer clinician for Cambridge University Hospitals, said: “This grant provides essential funding to perform the clinical validation study, which will begin next summer and involve about 250 patients. The results will underpin a submission for regulatory approval in the shape of UKCA and CE marking, which would allow us to test NeutroCheck using the device in an at-home setting for around 30 patients. This will in turn enable us to build an evidence base to support roll-out of the NeutroCheck solution across the NHS.”

- Advertisement -
Patricia Allen
Patricia Allen
is the Head of Content at EU-Startups. With a background in politics, Patricia has a real passion for how shared ideas across communities and cultures can bring new initiatives and innovations for the future. She spends her time bringing you the latest news and updates of startups across Europe, and curating our social media.
RELATED ARTICLES

Most Popular